

Genazopt Plus

Brinzolamide 1% and Brimonidine Tartrate 0.2%
Sterile Ophthalmic Suspension

Presentation

Genazopt Plus: Each ml ophthalmic suspension contains Brinzolamide USP 10 mg & Brimonidine Tartrate BP 2 mg.

Preservative: Sodium Perborate 0.01%

Pharmacological Action

Brinzolamide inhibits carbonic anhydrase in the ciliary processes of the eye to decrease aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Brimonidine Tartrate has a dual mechanism of action which works by allowing better fluid drainage from the eye and also by decreasing the amount of fluid formed in the eye.

Indications

Genazopt Plus ophthalmic suspension is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Dosage and Application

For elderly: The recommended dose is one drop in the affected eye(s) three times daily.

Pediatric dose: 2 years or above one drop three times daily.

Contraindications

Contraindicated in patients with hypersensitivity to any component of this medication, in patients receiving Monoamine Oxidase (MAO) inhibitor therapy.

Side Effects

Most commonly reported adverse reactions are eye discomfort, itching, redness, discharge, temporary blurred vision, dry eyes, feeling as if something is in eye, bitter or unusual taste in mouth, dizziness, drowsiness, tiredness and headache may occur.

Precautions

Caution should take for the patients who are sensitive to sulfonamide. Caution should be exercised in patients with severe renal impairment or hepatic impairment or severe cardiovascular disease. Remove soft contact lenses before use; may reinsert 15 minutes later.

Drug Interactions

Caution with antihypertensive, cardiac glycosides, tricyclic antidepressants, MAOIs. Concomitant high-dose salicylate may produce acid-base and electrolyte alterations. May be potentiated by CNS depressants (eg, alcohol, barbiturates, sedatives, anesthetics).

Use in Pregnancy and Lactation

Pregnancy Category C.

Lactation: It is not known whether Brinzolamide and Brimonidine Tartrate are excreted in human milk following topical ocular administration. Because many drugs are excreted in human milk therefore a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Overdose

Although no human data are available, electrolyte imbalance, development of an acidic state and possible nervous system effects may occur following an oral overdose of brinzolamide.

Storage Conditions

Store in a cool and dry place away from light. Keep out of reach of children. Do not touch the dropper tip to surface since this may contaminate the solution. Do not use after one month of first opening.

Commercial Pack

Genazopt Plus: Each plastic dropper bottle contains 5 ml sterile ophthalmic suspension.

Manufactured by :

 **GENERAL**
Pharmaceuticals Ltd.
Unit-2, Kaliakair, Gazipur, Bangladesh

22060224

Revision No.: 01